Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
1.110
+0.100 (9.90%)
At close: Oct 8, 2025, 4:00 PM EDT
1.120
+0.010 (0.90%)
After-hours: Oct 8, 2025, 7:04 PM EDT
Atossa Therapeutics Employees
Atossa Therapeutics had 15 employees as of December 31, 2024. The number of employees increased by 3 or 25.00% compared to the previous year.
Employees
15
Change (1Y)
3
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,914,533
Market Cap
143.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 15 | 3 | 25.00% |
| Dec 31, 2023 | 12 | 1 | 9.09% |
| Dec 31, 2022 | 11 | 3 | 37.50% |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | 8 | 2 | 33.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ATOS News
- 2 days ago - Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities - PRNewsWire
- 7 days ago - Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones - PRNewsWire
- 21 days ago - Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services - GlobeNewsWire
- 4 weeks ago - Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction - PRNewsWire
- 5 weeks ago - Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference - PRNewsWire
- 7 weeks ago - Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer - PRNewsWire
- 2 months ago - Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update - PRNewsWire
- 2 months ago - Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer - PRNewsWire